title: Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.
abstract: Over the last seven years, seven targeted agents have been approved in the treatment of advanced or metastatic renal cell cancer, changing the therapeutic approach and prognosis of the disease dramatically. The latest agent with demonstrated efficacy is axitinib (Inlyta(®)). This new generation of tyrosine kinase agent differs from previously existing agents by its greater activity potency of inhibition of vascular endothelial growth factor-receptor (VEGFR1-3). This efficacy has been tested in phase II and III clinical trials. Axitinib is the only targeted agent that benefits from recommended titration, with intra-patient dose escalation. The toxicity profile of the drug is tolerable. This paper reviews the mechanism of action of axitinib, its metabolism, and its pharmacokinetic profile. Clinical data of efficacy and safety is also detailed. The agent has been integrated in the international therapeutic guidelines, as a standard in treatment of renal cell cancer patients, previously treated through antiangiogenic therapy.
authors.affiliation: Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: Louis
authors.initials: L
authors.lastname: François
authors.forename: Amandine
authors.initials: A
authors.lastname: Quivy
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
keywords: axitinib; efficacy; renal cell cancer; safety